Advance Development in TDDS:

Drug in adhesive technology has become the preferred system for passive transdermal delivery; two areas of formulation research are focused on adhesives and excipients. Adhesive research focuses on customizing the adhesive to improve skin adhesion over the wear period, improve drug stability and solubility, reduce lag time, and increase the rate of delivery. Because a one-size-fits-all adhesive does not exist that can accommodate all drug and formulation chemistries, customizing the adhesive chemistry allows the transdermal formulator to optimize the performance of the transdermal patch

A rich area of research over the past 10 to 15 years has been focused on developing transdermal technologies that utilize mechanical energy to increase the drug flux across the skin by either altering the skin barrier (primarily the stratum corneum) or increasing the energy of the drug molecules. These so-called “active” transdermal technologies include iontophoresis (which uses low voltage electrical current to drive charged drugs through the skin), electroporation (which uses short electrical pulses of high voltage to create transient aqueous pores in the skin), sonophoresis (which uses low frequency ultrasonic energy to disrupt the stratum corneum), and thermal energy (which uses heat to make the skin more permeable and to increase the energy of drug molecules). Even magnetic energy, coined magnetophoresis, has been investigated as a means to increase drug flux across the skin

In the development of transdermal patches of TDDS a lot of process has been used. Many researchers are interested in the field of TDDS. Due to large benefit of the TDDS, many new researchers are going on in the development of transdermal dosage forms of newer drug via this system in the present day.

1. Loyd V. Allen Jr, Nicholas G. Popovich, Howard C. Ansel. Pharmaceutical dosage forms and drug delivery systems, 8th Edition., Wolter Kluwer Publishers,New Delhi, 2005 pp. 298-299
2. Kumar R, Philip A. Modified Transdermal Technologies: Breaking the Barriers of Drug Permeation via the Skin. Trop J Pharm Res. 2007, 6(1):633-644.
3. Brahmankar.D.M, Jaiswal.S.B, Biopharmaceutics and pharmacokinetics A Teatise. Vallabh Prakashan, Delhi1995, 335-371.
4. Ansel.H.C, Loyd.A.V, Popovich.N.G, Pharmaceutical dosage forms and drug delivery systems, Seventh edition, Lippincott Williams and Willkins publication.
5. Skin available at; en.wikipedia.or/wiki/skin
6. Bromberg L. Cross linked polyethylene glycol networks as reservoirs for protein delivery, Apply Poly Sci 1996, 59, 459-466.
7. Verma PRP, Iyer SS. Transdermal delivery of propranolol using mixed grades of eudragit: Design and in vitro and in vivo evaluation, Drug Dev Ind Pharm 2000, 26, 471-476
8. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics, AAPS PharmSciTech 2007, 8(1), Article 2.
9. Gannu R, Vamshi Vishnu Y, Kishan V, Madhusudan Rao Y. Development of nitrendipine transdermal patches: In vitro and ex vivo characterization, Current Drug Delivery 2007, 4, 69-76.
10. Chung SJ. Future drug delivery research in South Korea, J Controlled Release 1999, 62, 73 79.
11. Chung SJ. Future drug delivery research in South Korea, J Controlled Release 1999, 62, 73 79.
12. Izumoto T, Aioi A, Uenoyana S, Kariyama K, Azuma M. Relationship between the transference of drug from a transdermal patch andphysicochemical properties, Chem Pharm Bull (Tokyo) 1992, 40, 456-458.
13. Gordon RA, Peterson TA. Four myths about transdermal drug delivery, Drug Delivery Technology 2003, 3, 1-7.
14. Williams AC, Barry BW. Penetration enhancers, Advanced drug delivery reviews 2004, 56, 603-618.
15. Shin SC, Shin EY, Cho CY. Enhancing effects of fatty acids on piroxicam permeation through rat skins, Drug Dev Ind Pharm. 2000, 26, 563-566.
16. Pocius AV. Adhesives. In: Howe- Grants M, Ed. Kirk-Othmer Encyclopedia of Chemical Technology. New York, Wiley-Interscience. 1991; 445-466.
17. Walters KA. Transdermal drug delivery systems In: Swarbick K, Boylan JC, eds. Encyclopedia of pharmaceutical technology. New York, Marcel Dekker Inc. 1997; 253-293.
18.Tan HS, Pfister WR. Pressure sensitive adhesives for transdermal drug delivery, Pharm Sci Technol Today 1999, 2, 60-69.
19. Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems. Part I: Selection and formulationconsiderations, Med Device Technol 1990, 1, 48-55.
20. Godbey KJ. Improving patient comfort with nonocclusive transdermal backings, American Association of Pharmaceutical Scientists 1996, 1-2.
21. Richard H Guy & Jonathan Hadgraft, Drugs and The Pharmaceutical Sciences, Marcel Dekker, Volume 123, Transdermal Drug Delivery, Chapter 5 : “Iontophoresis” Pg No. 199 – 226, Chapter 6 : “Skin Electroporation for Transdermal and Topical Drug Delivery” Pg No. 22 – 254, Chapter 7 : “Sonophoresis” Pg No. 255 – 284, Chapter 10 : “Minimally Invasive Systems for Transdermal Drug Delivery” Pg No. 327 – 360
22. Nakano Yoshihisa et al., “Dosage and Design of Transdermal Patch”, Natto journal, Vol. 39, (2001), 60 – 64
23. Sateesh Kandavilli, Vinod Nair, and Ramesh Panchagnula Pharmaceutical Technology : May 2002 : “Polymers in Transdermal Drug Delivery Systems” : Page No. 62 – 80 .
24. Baker W and Heller J. ”Material Selection for Transdermal Delivery Systems”, In Transdermal Drug Delivery: Developmental Issues .
Wiechers J. Use of chemical penetration enhancers in Transdermal drug delivery-possibilities and difficulties. Acta pharm. 1992 : 4: 123.
25. Yamamoto T, Katakabe k, Akiyoshi K, Kan K and Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. Diabetesres. Clin. Pract. 1990; 8: 19-22.13. Al- Khamis K, Davis S.S and Hadgraft J. Microviscosity and drug release from topical gel formulations. Pharm. Res. 1986; 3: 214-217.
26. Anon. Transdermal delivery systems-general drug release standards. Pharmacopeial Forum, 1980; 14: 3860-3865.
27. Mayorga P, Puisieux F and Couarraze G.Formulation study of a Transdermal delivery system of primaquine. Int. J. pharm. 1996; 132: 71-79.
28. Deo M.R, Sant V.P,Parekh S.R, Khopade A.J and Banakar U.V. Proliposome-based Transdermal delivery of levonorgestrel. Jour. Biomat. Appl. 1997; 12: 77-88.
29. Yan-yu X, Yun- mei S, Zhi-Peng C and Qi-nerg P. Preparation of silymarin proliposomes; A new way to increase oral bioavailability ofsilymarin in beagle dogs. Int. pharm. 2006; 319: 162-168.
30. Crawford R.R and Esmerian O.K. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J. Pharm. Sci. 1997
31.Crawford R.R and Esmerian O.K. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J. Pharm. Sci. 1997;60:312- 314.
32. Research Initiatives, J.Hadgraft and R.H.Guys, Eds. Marcel Dekker, Inc.,New york 1989 pp. 293-311
33. Wade A and Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association 1994; 362- 366.
34. Lec S.T, Yac S.H, Kim S.W and Berner B. One way membrane for Transdermal drug delivery systems / system optimization. Int. J Pharm. 1991; 77: 231 - 237.
35. Vyas S.P and Khar R.K. Targetted and controlled Drug Delivery Novel carrier system1st Ed., CBS Publishers and distributors, New Delhi, 2002; 411-447.
36. Singh J, Tripathi K.T and SakiaT.R. Effect of penetration enhancers on the invitro transport of ephedrine through rate skin and human epidermis from matrix based Transdermal formulations. Drug Dev. Ind. Pharm. 1993; 19: 1623-1628.
37. Ryan D. Gordon, and Tim A. Peterson, transdermal drug delivery, drug delivery technology.



Subscribe to Pharmatutor Alerts by Email



Subscribe to RSS headline updates from:
Powered by FeedBurner